MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
RNA Avidity Biosciences
- 31.820
- +0.770+2.48%
Close Dec 20 16:00 ET
- 31.820
- 0.0000.00%
Post 20:01 ET
3.80BMarket Cap-11.05P/E (TTM)
32.630High30.850Low2.93MVolume30.920Open31.050Pre Close93.33MTurnover3.17%Turnover RatioLossP/E (Static)119.31MShares56.00052wk High2.53P/B2.94BFloat Cap8.86052wk Low--Dividend TTM92.43MShs Float56.000Historical High--Div YieldTTM5.73%Amplitude4.825Historical Low31.829Avg Price1Lot Size
About Avidity Biosciences Company
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Company Profile
SymbolRNA
Company NameAvidity Biosciences
Listing DateJun 12, 2020
Issue Price18.00
Founded2012
CEOMs. Sarah Boyce
MarketNASDAQ
Employees253
Fiscal Year Ends12-31
Address10578 Science Center Drive,Suite 125
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-401-7900
Company Executives
- Name
- Position
- Salary
- Sarah Boyce
- Director, President and Chief Executive Officer
- 11.14M
- Michael F. Maclean
- Chief Financial Officer, Chief Business Officer and Principal Accounting Officer
- 4.48M
- Eric Mosbrooker
- Chief Strategy Officer
- 235.31K
- Teresa McCarthy
- Chief Human Resources Officer
- 3.73M
- Dr. W. Michael Flanagan
- Chief Scientific and Technical Officer
- 4.89M
- Dr. Troy E. Wilson, PhD, J.D.
- Chairman of the Board
- 260.31K
- Dr. Arthur A. Levin,PhD
- Distinguished Scientist and Strategic Leader and Director
- 3.03M
- Dr. Edward M. Kaye, M.D.
- Independent Director
- 244.31K
- Simona Skerjanec, M.B.A.
- Independent Director
- --
- Tamar Thompson
- Independent Director
- 239.31K
- Jean Kim
- Independent Director
- 237.81K
- Carsten Boess
- Independent Director
- 245.31K
- Dr. Noreen Roth Henig, M.D.
- Independent Director
- 245.81K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.